The first subject has been dosed in a phase 1 clinical trial of an oral proteolysis-targeting chimera protein degrader to treat neurodegenerative diseases, according to the manufacturer.
According to a release from Arvinas, ARV-102 was shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2) in preclinical studies. This property was crucial to efficacy as increased activity and expressions of LRRK2 is a sign of pathogenesis of neurological diseases — including Parkinson’s disease and progressive supranuclear palsy — at the genetic level, per the